At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Harold J. Burstein, MD, PhD, of Dana-Farber Cancer Institute, Boston, MA, discusses the controversy regarding the optimal approach to prognostic and predictive genomic testing for breast cancer. The Oncotype DX® Breast Cancer Assay, a 21-gene assay, may complement clinicopathological factors for defining subpopulations in breast cancer patients that would benefit from adjuvant chemotherapy.
This content is supported by Genomic Health, Inc.
